

Jordbro, 14 November 2014

Invitation to telephone conference due to Recipharm's acquisition of Lusomedicamenta

The contract development and manufacturing organisation, Recipharm AB acquired yesterday 13 November the Lisbon based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A for SEK 1 billion.

Due to the announcement of the acquisition yesterday a telephone conference with a web presentation and Q&A will be held today at 09:00 am CET.

Yesterday's press release in full is attached through the link at the end of this announcement.

To participate in the conference, please dial:

From Sweden, tel: +46 8 506 443 86
From Denmark, tel: +45 32 71 42 62
From Finland, tel: +358 9 8171 0375
From Norway, tel: +47 21 06 61 13
From the UK, tel: +44 20 7153 9154
From Germany, tel: +49 69 2017 44 210
From France, tel: +33 1 70 70 95 02
From Spain, tel: +34 914 142 009
From Switzerland, tel: +41 44 580 65 22
From the US, tel: +1 877 423 0830
From Italy, tel: +39 02 3600 6663
From Portugal: +49 69 20 17 44 210

Pin code for participants: 862216#

To access the presentation use the following link:

<http://event.onlineseminarsolutions.com/r.htm?e=886795&s=1&k=805E770D4F476C044CCE2004D68E488F>

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10
Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 250 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm's turnover is approximately SEK 2.6 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain and Italy and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm.

For more information on Recipharm and our services, please [visit www.recipharm.com](http://www.recipharm.com).